There is a real pharmacological connection between citicoline and nicotine, and it is not a marketing invention. Citicoline supplies choline, choline makes acetylcholine, and acetylcholine acts at nicotinic receptors, the same receptor family nicotine binds. That connection has been demonstrated experimentally. The question worth answering is whether it amounts to anything for a person who smokes or vapes, and the literature answers that question far less generously than the mechanism suggests.
Nothing here is medical advice. Citicoline is not approved by the FDA to diagnose, treat, cure, or prevent nicotine dependence or any other condition, and it is not a smoking cessation aid. Effective, evidence-based cessation treatments exist, including nicotine replacement therapy and prescription medications. Anyone trying to quit should discuss those with a clinician rather than substituting a supplement for them.
Key Takeaways
- No human study has tested citicoline for quitting smoking or vaping. Not one trial, cohort, or case series exists on cessation[1][2][3]
- The mechanistic link is real: citicoline’s effects in one rat model were completely blocked by alpha 7 nicotinic receptor antagonists[4]
- The 1983 study often cited is a lethal-dose toxicity experiment in mice given intravenous nicotine, which has nothing to do with smoking[1]
- The 2025 vaping study is 35 rats, 7 per group, and gave CDP-choline during the final three weeks of a six-week exposure[2]
- One mouse study runs the opposite direction: nicotine boosted citicoline’s effects, not the reverse[3]
- Human nicotinic-receptor work with CDP-choline exists but targets sensory gating in a schizophrenia-related model, not nicotine dependence[5]
The Receptor Link Is Genuine
Start with what is actually established, because it is the part that gives this topic its legs. Nicotinic acetylcholine receptors are named for nicotine because nicotine binds them, but their endogenous ligand is acetylcholine. Citicoline delivers choline, which is the rate-limiting precursor for acetylcholine synthesis. So there is a direct, well-understood chain from a citicoline capsule to nicotinic receptor activity.
That chain has been tested rather than assumed. In a rat study of prepulse inhibition, a measure of sensorimotor gating, scopolamine was used to disrupt gating and CDP-choline at 250 mg/kg intraperitoneally reversed the disruption. The researchers then blocked the effect with mecamylamine, a non-specific nicotinic antagonist, and with methyllycaconitine, a selective alpha 7 nicotinic antagonist. Both completely blocked CDP-choline’s reversal[4].
That is a clean mechanistic demonstration. CDP-choline was working through central alpha 7 nicotinic receptors, because removing those receptors from the equation removed the effect. Worth noting alongside it: CDP-choline at 75, 250, and 500 mg/kg had no effect on prepulse inhibition in undisrupted animals[4]. It corrected a deficit rather than enhancing normal function, which is a pattern that recurs across the citicoline literature.
Human work has followed this thread. A randomized, double-blind, placebo-controlled study in 30 healthy volunteers combined CDP-choline at 500 mg with galantamine at 16 mg as a deliberate alpha 7 nicotinic strategy, and found improved P50 sensory gating in participants who were poor gaters at baseline, with no gating effect in good gaters[5]. That is a real human study with a real nicotinic mechanism. It is a study about sensory gating as a schizophrenia-related endophenotype, not about nicotine dependence, and it combined citicoline with a prescription drug.
The 1983 Study Is Not About Smoking
The oldest citation in this area is regularly presented as showing that citicoline protects against nicotine. What it examined was acute lethal toxicity. A group of mice received CDP-choline orally at 1 g/kg for four days while another group received a 0.25 percent agar suspension. The animals were then divided into subgroups of 10 and given increasing intravenous doses of nicotine bitartrate. Comparing the two groups, the authors observed a remarkable difference in the LD50, the dose lethal to half the animals[1].
An LD50 shift is a toxicology finding. It describes how much of a poison it takes to kill an animal, and the model here is acute nicotine poisoning by intravenous injection. Nobody who smokes or vapes is experiencing acute nicotine poisoning. The dose is also far outside anything relevant: 1 g/kg in a mouse, scaled between species by body surface area, corresponds to roughly 81 mg/kg in a human, or about 5.7 grams a day for a 70 kg adult, which is more than eleven times a common 500 mg capsule.
The study is a legitimate piece of 1983 pharmacology. It simply does not bear on the question people are asking when they search this topic.
The Vaping Study Is Small and Its Design Matters
The most recent and most directly relevant work exposed rats to e-cigarette vapor and then tested CDP-choline during withdrawal. Thirty-five adult male Wistar rats were assigned to five groups: room air control, e-cigarette exposure, e-cigarette exposure plus CDP-choline, e-cigarette quitting plus CDP-choline, and CDP-choline alone. Exposure ran six weeks, with CDP-choline given during the final three. Anxiety-like behavior was assessed with the light-dark box, and serum nicotine, cotinine, adrenaline, and beta-endorphin were measured by mass spectrometry[2].
Chronic e-cigarette exposure raised serum nicotine, cotinine, adrenaline, and beta-endorphin and was associated with withdrawal-induced anxiety. CDP-choline reduced serum nicotine and cotinine concentrations, normalized adrenaline and beta-endorphin, and improved behavior, with animals spending more time in the light chamber and stretching less[2].
Five groups across 35 animals means seven rats per group, which is a small sample for behavioral endpoints that are inherently variable. The light-dark box measures anxiety-like behavior in a rodent, which is a proxy for withdrawal distress rather than a measurement of it, and rats were not choosing whether to keep vaping. Craving, relapse, and the decision to smoke again are the outcomes that define smoking cessation, and no animal model captures them well.
The reduction in serum nicotine and cotinine is the most interesting finding and the one most in need of explanation. Lower cotinine after the same exposure implies altered nicotine metabolism or clearance. If that held in humans it could matter, and it could cut either way, since faster nicotine clearance is associated with heavier smoking in people trying to maintain nicotine levels. The study does not resolve the mechanism, and no human pharmacokinetic study has looked.
One Study Points the Other Way Entirely
A mouse study is sometimes listed as supporting a citicoline and nicotine interaction without noting which direction it runs. Researchers assessed anxiety with the elevated plus maze and depression-like behavior with the forced swim test. Nicotine by itself was anxiogenic and depressive-like, decreasing open-arm time and entries and increasing immobility. Citalopram and citicoline each separately produced anxiolytic and antidepressant-like effects[3].
Then the key result: a subthreshold dose of nicotine potentiated the citalopram and citicoline effects on open-arm time and immobility[3]. Nicotine amplified what citicoline did. That is nicotine helping citicoline, which is nearly the reverse of the claim it gets cited for, and it is not a helpful message for someone trying to stop using nicotine.
What Would Actually Answer the Question
The gap here is not subtle, and it is not expensive to close. Smoking cessation has well-established trial methodology: randomize smokers who want to quit to drug or placebo, set a quit date, and measure biochemically verified abstinence at six and twelve months. That design has been run hundreds of times for other compounds. It has never been run for citicoline.
Until it is, the accurate statement is that citicoline acts on the same receptor family nicotine does, that this has been demonstrated in animals and in a human sensory gating study, and that nobody has tested whether it changes anything for a person trying to quit. Mechanism is not outcome. The citicoline literature contains several instances where a well-supported mechanism failed to produce a clinical result when finally tested properly.
Meanwhile, treatments with actual cessation trial evidence do exist, including nicotine replacement therapy and prescription medications, along with behavioral support. Someone who substitutes an untested supplement for one of those has traded a treatment that works for one nobody has measured. That is the practical risk in this topic, and it is larger than any risk from citicoline itself.
A Note on What Citicoline Is Not Being Claimed to Do Here
It is worth separating two questions that get blurred. One is whether citicoline helps people quit nicotine. Nothing in the literature supports that, and this article has said so repeatedly.
The other is whether citicoline might address cognitive effects associated with nicotine withdrawal, such as difficulty concentrating in the first weeks after quitting. That is a more modest question and, in principle, a more answerable one, since citicoline’s attention and cognitive endpoints have been examined in other populations. It has also never been studied in people quitting nicotine. Anyone considering it for that purpose should know they are ahead of the evidence, not behind it, and should raise it with the clinician supporting their quit attempt, particularly if prescription cessation medications are involved.
Frequently Asked Questions
Does citicoline help you quit smoking?
No study has tested it. There is no randomized trial, cohort study, or case series examining citicoline for smoking or vaping cessation in humans. The existing research is entirely in mice and rats and does not measure craving, relapse, or abstinence.
Is there a real link between citicoline and nicotine receptors?
Yes. Citicoline supplies choline for acetylcholine synthesis, and acetylcholine acts at nicotinic receptors. In one rat study, CDP-choline’s effect on sensorimotor gating was completely blocked by both a non-specific nicotinic antagonist and a selective alpha 7 antagonist, showing the effect ran through those receptors.
What did the 1983 nicotine study actually show?
It was an acute toxicity experiment. Mice given CDP-choline orally at 1 g/kg for four days, then injected intravenously with increasing doses of nicotine bitartrate, showed a higher LD50 than controls. That is a lethal-dose measurement in nicotine poisoning, not a finding about smoking, and the dose scales to roughly 5.7 grams a day in an adult.
Did the vaping study show citicoline helps with withdrawal?
In rats, partly. CDP-choline reduced serum nicotine and cotinine, normalized adrenaline and beta-endorphin, and reduced anxiety-like behavior in a light-dark box. The study used 35 rats across five groups, so seven per group, and rodent anxiety behavior is a proxy for withdrawal distress rather than a measure of it.
Does nicotine affect how citicoline works?
One mouse study found that a subthreshold dose of nicotine potentiated the anxiolytic and antidepressant-like effects of both citalopram and citicoline. That is nicotine amplifying citicoline rather than citicoline offsetting nicotine, which is the opposite of how the study is often cited.
Is it safe to take citicoline while using nicotine replacement therapy?
No interaction study has examined that combination, so the honest answer is that nobody has checked. Anyone using prescription cessation medication or nicotine replacement should raise any supplement with the clinician supporting their quit attempt rather than adding it independently.
References
- Grau T, et al. Study on the protection of CDP-choline against nicotine intoxication. Arzneimittel-Forschung (1983). PMID 6684456
- Barakat R, et al. E-cigarette exposure and CDP choline modulate withdrawal-induced anxiety and hormonal levels in rats. Scientific Reports (2025). PMID 41315627
- Khakpai F, et al. The effect of nicotine on antidepressant and anxiolytic responses induced by citalopram and citicoline in mice. Acta Neurobiologiae Experimentalis (2023). PMID 37493535
- Uslu G, et al. CDP-choline attenuates scopolamine induced disruption of prepulse inhibition in rats: involvement of central nicotinic mechanism. Neuroscience Letters (2014). PMID 24708927
- Choueiry J, et al. Combining CDP-choline and galantamine: Effects of a selective alpha 7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers. Journal of Psychopharmacology (2019). PMID 30920339
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice. As an Amazon Associate we earn from qualifying purchases.
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
